Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Alcon Research, Ltd. v. Micro Labs Ltd., 14-0014 (D. Del.) |
Jan. 9, 2014 |
Hon. Sue L. Robinson |
Travatan Z® (travoprost ophthalmic solution) |
8,268,299 |
Biodelivery Sciences International, Inc. v. RB Pharma. Ltd., IPR2014-00325 (PTAB) |
Jan. 15, 2014 |
N/A |
Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride) |
8,475,832 |
Amneal Pharma., LLC v. Endo Pharma., Inc., IPR2014-00360 (PTAB) |
Jan. 16, 2014 |
N/A |
Opana® ER (oxymorphone hydrochloride extended-release tablets) |
8,329,216 |
Amneal Pharma., LLC v. Endo Pharma., Inc., IPR2014-00361 (PTAB) |
Jan. 16, 2014 |
N/A |
Opana® ER (oxymorphone hydrochloride extended-release tablets) |
8,309,122 |
Takeda Pharma. Co., Ltd. v. Mylan Inc., 14-0314 |
Jan. 21, 2014 |
Hon. Lucy H. Koh |
Dexilant® (dexlansoprazole delayed-release capsules) |
7,339,064 |
Lyne Labs., Inc. v. Lupin Ltd., 14-10153 (D. Mass.) |
Jan. 21, 2014 |
Hon. Nathaniel M. Gorton |
Phoslyra® (calcium acetate oral solution) |
8,591,938 |
Lyne Labs., Inc. v. Par Pharma., Inc., 14-10154 |
Jan. 21, 2014 |
Hon. Nathaniel M. Gorton |
Phoslyra® (calcium acetate oral solution) |
8,591,938 |
Millennium Pharma., Inc. v. Teva Pharma. USA, Inc., 14-0093 (D. Del.) |
Jan. 22, 2014 |
Hon. Gregory M. Sleet |
Velcade® (bortezomib injection) |
6,713,446 |
Cadence Pharma., Inc. v. Wockhardt Ltd., 14-0094 (D. Del.) |
Jan. 22, 2014 |
Hon. Leonard P. Stark |
Ofirmev® (acetaminophen solution) |
6,028,222 |
Eli Lilly and Co. v. Glenmark Generics Inc., USA, 14-0104 (S.D. Ind.) |
Jan. 23, 2014 |
Hon. Tanya W. Pratt |
Alimta® (pemetrexed disodium for injection) |
7,772,209 |
Eli Lilly and Co. v. Par Pharma. Cos., Inc., 14-0109 (S.D. Ind.) |
Jan. 23, 2014 |
Hon. Sarah E. Barker |
Effient® (prasugrel hydrochloride tablets) |
8,404,703 |
Cadence Pharma., Inc. v. Wockhardt Ltd., 14-0485 (D.N.J.) |
Jan. 23, 2014 |
Hon. Renee M. Bumb |
Ofirmev® (acetaminophen solution) |
6,028,222 |
AbbVie Inc. v. Roxane Labs., Inc., 14-0085 (S.D. Ohio) |
Jan. 23, 2014 |
Hon. Michael H. Watson |
Norvir® (ritonavir tablets) |
8,470,347 |
Eli Lilly and Co. v. Par Pharma. Cos., Inc., 14-0508 (D.N.J.) |
Jan. 24, 2014 |
Hon. Claire C. Cecchi |
Effient® (prasugrel hydrochloride tablets) |
8,404,703 |
Alcon Research, Ltd. v. Cipla Ltd., 14-0131 (S.D. Ind.) |
Jan. 29, 2014 |
Hon. Richard L. Young |
Pataday® (olopatadine hydrochloride ophthalmic solution) |
6,995,186 |
Novartis Pharma. Corp. v. Noven Pharma., Inc., 14-0111 (D. Del.) |
Jan. 30, 2014 |
Hon. Richard G. Andrews |
Exelon® Patch (rivastigmine transdermal system or extended release film) |
6,316,023 |
Sanofi-Aventis U.S. LLC v. Eli Lilly and Co., 14-0113 |
Jan. 30, 2014 |
Hon. Richard G. Andrews |
Lantus® / Lantus® SoloSTAR® (insulin glargine [rDNA origin] for injection) |
8,556,864 |
Teijin Ltd. v. Ranbaxy Labs., Ltd., 14-0117 (D. Del.) |
Jan. 31, 2014 |
Hon. Sue L. Robinson |
Uloric® (febuxostat tablets) |
6,225,474 |
Forest Labs., Inc. v. Teva Pharma. USA, Inc., 14-0121 (D. Del.) |
Jan. 31, 2014 |
Hon. Leonard P. Stark |
Namenda XR® (memantine hydrochloride extended-release capsules) |
5,061,703 |
Cephalon, Inc. v. Actavis LLC, 14-0122 (D. Del.) |
Jan. 31, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride) |
8,445,524 |
Senju Pharma. Co., Ltd. v. Lupin, Ltd., 14-0667 (D.N.J.) |
Jan. 31, 2014 |
Hon. Jerome B. Simandle |
Prolensa® (bromfenac ophthalmic solution 0.07%) |
8,129,431 |
Novartis Pharma. Corp. v. Dr. Reddy’s Labs., Ltd., 14-0157 (D. Del.) |
Feb. 5, 2014 |
Hon. Leonard P. Stark |
Gleevec® (imatinib mesylate capsules) |
6,894,051 |
Forest Labs., Inc. v. Glenmark Generics Inc., 14-0159 |
Feb. 6, 2014 |
Hon. Sue L. Robinson |
Savella® (milnacipran hydrochloride tablets) |
6,602,911 |
Fresenius Kabi USA, LLC v. Dr. Reddy’s Lab., Ltd., |
Feb. 6, 2014 |
Hon. Sue L. Robinson |
Diprivan® (propofol injectable emulsion) |
8,476,010 |
Fresenius Kabi USA, LLC v. Watson Labs., Inc. 14-0161 (D. Del.) |
Feb. 6, 2014 |
Hon. Sue L. Robinson |
Diprivan® (propofol injectable emulsion) |
8,476,010 |
Novartis Pharma. Corp. v. Dr. Reddy’s Labs., Ltd., 14-0785 (D.N.J.) |
Feb. 6, 2014 |
Hon. Claire C. Cecchi |
Gleevec® (imatinib mesylate capsules) |
6,894,051 |
Teijin Ltd. v. Hetero USA, Inc., 14-0166 (D. Del.) |
Feb. 7, 2014 |
Hon. Sue L. Robinson |
Uloric® (febuxostat tablets) |
6,225,474 |
Teijin Ltd. v. Lupin Ltd., 14-0184 (D. Del.) |
Feb. 12, 2014 |
Hon. Sue L. Robinson |
Uloric® (febuxostat tablets) |
6,225,474 |
Teijin Ltd. v. Roxane Labs., Inc., 14-0189 (D. Del.) |
Feb. 12, 2014 |
Hon. Sue L. Robinson |
Uloric® (febuxostat tablets) |
6,225,474 |
Merck Sharp & Dohme Corp. v. Xellia Pharma. APS, 14-0199 (D. Del.) |
Feb. 14, 2014 |
Hon. Richard G. Andrews |
Cancidas® (caspofungin acetate injection) |
5,952,300 |
Forest Labs., Inc. v. Apotex Corp., 14-0200 (D. Del.) |
Feb. 14, 2014 |
Hon. Leonard P. Stark |
Namenda XR® (memantine hydrochloride extended-release capsules) |
8,039,009 |
Salix Pharma., Inc. v. Novel Labs., Inc., 14-0213 (D. Del.) |
Feb. 18, 2014 |
Hon. Gregory M. Sleet |
Apriso® (mesalamine extended-release capsules) |
6,551,620 |
Otsuka Pharma. Co., Ltd. v. Torrent Pharma. Ltd., 14-1078 (D.N.J.) |
Feb. 18, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Merck Sharp & Dohme Corp. v. Xellia Pharma. APS, 14-0124 (W.D. Wis.) |
Feb. 18, 2014 |
Hon. Stephen L. Crocker |
Cancidas® (caspofungin acetate injection) |
5,952,300 |
AbbVie Inc. v. Aurobindo Pharma Ltd., 14-0215 |
Feb. 19, 2014 |
Hon. Gregory M. Sleet |
Zemplar® (paricalcitol injection) |
5,597,815 |
Meda Pharma. Inc. v. Perrigo Israel Pharma. Ltd., 14-1241 (D.N.J.) |
Feb. 25, 2014 |
Hon. Joel A. Pisano |
Astepro® (azelastine hydrochloride nasal spray) |
8,518,919 |
Sanofi v. Glenmark Generics Inc., USA, 14-0264 (D. Del.) |
Feb. 26, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
8,318,800 |
Sanofi v. Watson Labs., Inc., 14-0265 (D. Del.) |
Feb. 26, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
8,318,800 |
Takeda Pharma. USA, Inc. v. Watson Labs., Inc., 14-0268 (D. Del.) |
Feb. 27, 2014 |
Hon. Sue L. Robinson |
Colcrys® (colchicine, USP) |
7,601,758 |
Lyne Labs., Inc. v. Roxane Labs., Inc., 14-10460 |
Feb. 27, 2014 |
Hon. Nathaniel M. Gorton |
Phoslyra® (calcium acetate oral solution) |
8,591,938 |
Antares Pharma, Inc. v. Medac Pharma, Inc., 14-0270 (D. Del.) |
Feb. 28, 2014 |
Hon. Sue L. Robinson |
OtrexupTM (methotrexate injection) |
8,480,631 |
Bausch & Lomb Inc. v. Sandoz Inc., 14-1325 |
Mar. 2, 2014 |
Hon. Noel L. Hillman |
Bepreve® (bepotastine besilate 1.5% solution/drops) |
6,780,877 |
Novartis Pharma. Corp. v. Pharmaceutics Int’l, Inc., 14-1347 (D.N.J.) |
Mar. 3, 2014 |
Hon. Susan D. Wigenton |
Zometa® (zoledronic acid injection) |
8,324,189 |
Janssen Products, L.P. v. Lupin Ltd., 14-1370 |
Mar. 4, 2014 |
Hon. William H. Walls |
Prezista® (darunavir tablets) |
8,518,987 |
Roxane Labs., Inc. v. Camber Pharma., Inc., 14-0232 |
Mar. 4, 2014 |
Hon. Gregory L. Frost |
calcium acetate capsules |
8,563,032 |
Sanofi v. Alkem Labs. Ltd., 14-0292 (D. Del.) |
Mar. 6, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
7,323,493 |
Sanofi v. First Time US Generics LLC, 14-0293 |
Mar. 6, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
8,318,800 |
Sanofi v. Sun Pharma Global FZE, 14-0294 (D. Del.) |
Mar. 6, 2014 |
Hon. Richard G. Andrews |
Multaq® (dronedarone tablets) |
7,323,493 |
Allergan, Inc. v. Actavis PLC, 14-0188 (E.D. Tex.) |
Mar. 6, 2014 |
Hon. Rodney Gilstrap |
Restasis® (cyclosporine ophthalmic emulsion 0.05%) |
8,629,111 |
Medac Pharma., Inc. v. Antares Pharma., Inc., 14-1498 (D.N.J.) |
Mar. 7, 2014 |
Hon. Jerome B. Simandle |
OtrexupTM (methotrexate injection) |
8,664,231 |
Eli Lilly and Co. v. Accord Healthcare, Inc. USA, 14-0389 (S.D. Ind.) |
Mar. 12, 2014 |
Hon. Sarah Evans Barker |
Effient® (prasugrel hydrochloride tablets) |
5,288,726 |
Eli Lilly and Co. v. Accord Healthcare, Inc. USA, 14-1643 (D.N.J.) |
Mar. 13, 2014 |
Hon. Claire C. Cecchi |
Effient® (prasugrel hydrochloride tablets) |
5,288,726 |
Cephalon, Inc. v. Sun Pharma Global FZE, 14-0333 (D. Del.) |
Mar. 14, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride) |
8,609,863 |
Cephalon, Inc. v. Dr. Reddy’s Labs., Ltd., 14-0334 (D. Del.) |
Mar. 14, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride) |
8,609,863 |
Cephalon, Inc. v. Emcure Pharma Ltd., 14-0335 |
Mar. 14, 2014 |
Hon. Gregory M. Sleet |
Treanda® (bendamustine hydrochloride) |
8,445,524 |
Sanofi v. Sun Pharma Global FZE, 14-1844 (N.D. Ill.) |
Mar. 14, 2014 |
Hon. Ruben Castillo |
Multaq® (dronedarone tablets) |
7,323,493 |
Astellas US LLC v. Emcure Pharma. USA, Inc., 14-1665 (D.N.J.) |
Mar. 14, 2014 |
Hon. Stanley R. Chesler |
Adenoscan® (adenosine injection) |
5,731,296 |
Otsuka Pharma. Co., Ltd. v. Amneal Pharma., LLC, 14-1688 (D.N.J.) |
Mar. 14, 2013 |
Hon. Mary L. Cooper |
Abilify® (aripiprazole oral solution) |
7,053,092 |
Pfizer Inc. v. Torrent Pharma. Ltd., 14-1704 (D.N.J.) |
Mar. 17, 2014 |
Hon. Mary L. Cooper |
Viagra® (sildenafil citrate tablets) |
6,469,012 |
Cephalon, Inc. v. Emcure Pharma Ltd., 14-1705 |
Mar. 17, 2014 |
Hon. Peter G. Sheridan |
Treanda® (bendamustine hydrochloride) |
8,445,524 |
Pfizer Inc. v. Torrent Pharma. Ltd., 14-1831 (S.D.N.Y.) |
Mar. 17, 2014 |
Hon. Paul A. Engelmayer |
Viagra® (sildenafil citrate tablets) |
6,469,012 |
Bristol-Myers Squibb Co. v. Apotex, Inc., 14-0351 |
Mar. 19, 2014 |
Hon. Richard G. Andrews |
Baraclude® (entecavir tablets) |
5,206,244 |
Sanofi v. Alkem Labs. Ltd., 14-1957 (N.D. Ill.) |
Mar. 19, 2014 |
Hon. Ruben Castillo |
Multaq® (dronedarone tablets) |
7,323,493 |
UCB, Inc. v. Corepharma, L.L.C., 14-1788 (D.N.J.) |
Mar. 20, 2014 |
Hon. Faith S. Hochberg |
Metadate CD® (methylphenidate hydrochloride capsules) |
6,344,215 |
ViiV Healthcare UK Ltd. v. Lupin Ltd., 14-0369 (D. Del.) |
Mar. 21, 2014 |
Hon. Richard G. Andrews |
Epzicom® (abacavir sulfate / lamivudine tablets) |
6,417,191 |
Bayer Pharma AG v. Watson Labs., Inc., 14-1804 (D.N.J.) |
Mar. 21, 2014 |
Hon. Jose L. Linares |
Staxyn® (vardenafil hydrochloride tablets) |
8,613,950 |
Novartis Pharma. Corp. v. Gland Pharma Ltd., 14-1841 (D.N.J.) |
Mar. 21, 2014 |
Hon. Susan D. Wigenton |
Reclast® (zoledronic acid injection) |
8,052,987 |
Bausch & Lomb, Inc. v. Akorn, Inc., 14-1866 (D.N.J.) |
Mar. 24, 2014 |
Hon. Noel L. Hillman |
Bepreve® (bepotastine besilate ophthalmic solution) |
6,780,877 |
Novartis Pharma. Corp. v. Dr. Reddy’s Labs., Ltd., 14-0387 (D. Del.) |
Mar. 26, 2014 |
Hon. Leonard P. Stark |
Gleevec® (imatinib mesylate capsules) |
RE43,932 |
Mallinckrodt LLC v. Amneal Pharma. LLC, 14-0389 |
Mar. 27, 2014 |
Hon. Richard G. Andrews |
Pennsaid® (diclofenac sodium topical solution) |
8,217,078 |
Bausch & Lomb, Inc. v. Micro Labs. Ltd., 14-1974 (D.N.J.) |
Mar. 28, 2014 |
Hon. Noel L. Hillman |
Bepreve® (bepotastine besilate ophthalmic solution) |
6,780,877 |
Bausch & Lomb, Inc. v. Apotex, Inc., 14-1975 (D.N.J.) |
Mar. 28, 2014 |
Hon. Noel L. Hillman |
Bepreve® (bepotastine besilate ophthalmic solution) |
6,780,877 |
Otsuka Pharma. Co., Ltd. v. Wockhardt Bio AG, 14-1979 (D.N.J.) |
Mar. 28, 2014 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
8,017,615 |
Supernus Pharma. Inc. v. Actavis, Inc., 14-1981 (D.N.J.) |
Mar. 28, 2014 |
Hon. Renee M. Bumb |
Oxtellar XR™ (oxcarbazepine extended-release tablets) |
8,617,600 |